Clinical Trial Update: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. [Phase 2, Phase 3]

View source ↗

Summary

An update on a Phase 2/Phase 3 clinical trial evaluating SI-B001 in combination with Osimertinib for recurrent metastatic non-small cell lung cancer, with the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SI-B001
• TAGRISSO (osimertinib)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING